T
Theodore Colton
Researcher at Boston University
Publications - 97
Citations - 8115
Theodore Colton is an academic researcher from Boston University. The author has contributed to research in topics: Population & Breast cancer. The author has an hindex of 44, co-authored 94 publications receiving 7803 citations. Previous affiliations of Theodore Colton include Tufts University & Tufts Medical Center.
Papers
More filters
Journal Article
The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975.
Howard M. Leibowitz,Dean E. Krueger,Lucinda R Maunder,R C Milton,Mohandas Kini,H A Kahn,Rita J. Nickerson,J Pool,Theodore Colton,James P. Ganley,John I. Loewenstein,T R Dawber +11 more
TL;DR: This monograph presents the detailed protocols and record forms for screening and diagnostic examinations, definitions of the specific abnormalities and characteristics used to screen for each disease, criteria for suspicion and diagnosis of diseases, detailed tables of the basic data from the study, evaluation of quality of the data, and discussion of selected findings.
Journal ArticleDOI
Repurposing Diflunisal for Familial Amyloid Polyneuropathy A Randomized Clinical Trial
John L. Berk,Ole B. Suhr,Laura Obici,Yoshiki Sekijima,Steven R. Zeldenrust,Taro Yamashita,Michael A. Heneghan,Peter D. Gorevic,William J. Litchy,Janice F. Wiesman,Erik Nordh,Manuel Corato,Alessandro Lozza,Andrea Cortese,Jessica Robinson-Papp,Theodore Colton,Denis Rybin,Alice Bisbee,Yukio Ando,Shu-ichi Ikeda,David C. Seldin,Giampaolo Merlini,Martha Skinner,Jeffery W. Kelly,Peter J. Dyck +24 more
TL;DR: Among patients with familial amyloid polyneuropathy, the use of diflunisal compared with placebo for 2 years reduced the rate of progression of neurological impairment and preserved quality of life.
Journal ArticleDOI
Efficacy of Recombinant Human Erythropoietin in Critically Ill Patients: A Randomized Controlled Trial
Howard L. Corwin,Andrew Gettinger,Ronald G. Pearl,Mitchell P. Fink,Mitchell M. Levy,Marc J. Shapiro,Michael J. Corwin,Theodore Colton +7 more
TL;DR: In critically ill patients, weekly administration of a weekly dosing schedule of recombinant human erythropoietin (rHuEPO) reduces allogeneic RBC transfusion and increases hemoglobin.
Journal ArticleDOI
Adenocarcinoma and Barrett's esophagus. An overrated risk?
Stuart J. Spechler,Stuart J. Spechler,Alan H. Robbins,Alan H. Robbins,Hanna Bloomfield Rubins,Hanna Bloomfield Rubins,Miriam E. Vincent,Miriam E. Vincent,Timothy Heeren,Timothy Heeren,Wilhelm G. Doos,Wilhelm G. Doos,Theodore Colton,Theodore Colton,Elihu M. Schimmel,Elihu M. Schimmel +15 more
TL;DR: The risk of developing esophageal cancer in Barrett's esophagus has been estimated at about 10%. This estimate is based primarily on data concerning the prevalence of that association in series of hospitalized patients and autopsies.
Journal ArticleDOI
Adverse Health Outcomes in Women Exposed In Utero to Diethylstilbestrol
Robert H. Hoover,Marianne Hyer,Ruth M. Pfeiffer,Ervin Adam,Brian Bond,Andrea L. Cheville,Theodore Colton,Patricia Hartge,Elizabeth E. Hatch,Arthur L. Herbst,Beth Y. Karlan,Raymond Kaufman,Kenneth L. Noller,Julie R. Palmer,Stanley J. Robboy,Robert C. Saal,William C. Strohsnitter,Linda Titus-Ernstoff,Rebecca Troisi +18 more
TL;DR: In utero exposure of women to DES is associated with a high lifetime risk of a broad spectrum of adverse health outcomes, and the risks among exposed women were higher for those with vaginal epithelial changes than for those without such changes.